Targeted combination immunotherapy of cancer
AssigneeImmunomedics, Inc.
InventorsGary L. Griffiths, Hans J. Hansen
Life of this patent
Estimating the term…
Abstract
The invention provides compositions, methods and kits for effecting therapy of a tumor in a patient. The compositions comprise (A) a first conjugate comprising a targeting moiety, a first member of a binding pair, and a first therapeutic agent, wherein the targeting moiety selectively binds to a marker substance produced by or associated with the tumor; (B) optionally, a clearing composition; and (C) a second conjugate comprising a complementary member of the binding pair and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent. The methods comprise sequentially administering (A), (B), and (C) to a patient. The kits comprise (A), (B), and (C) in separate containers.
Claims37
A composition for effecting therapy of a tumor in a patient, comprising:
- (A) a first conjugate comprising a targeting moiety, a first member of a binding pair, and a first therapeutic agent, wherein the targeting moiety selectively binds to a marker substance produced by or associated with the tumor;
- (B) optionally, a clearing agent;
- and
- (C) a second conjugate comprising a complementary member of said binding pair and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent,
- wherein the binding pair is selected from the group consisting of (a) complementary DNA fragments, (b) complementary peptide oligonucleotides, and (c) corresponding enzymes and prodrug substrates.
A composition for effecting therapy of a tumor in a patient, comprising:
- (A) a first conjugate comprising a targeting moiety, a first member of a binding pair, and a first therapeutic agent, wherein the targeting moiety selectively binds to a marker substance produced by or associated with the tumor;
- (B) optionally, a clearing agent;
- and
- (C) a second conjugate comprising a complementary member of said binding pair and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent, wherein the clearing agent is anti-idiotypic to the targeting moiety of the first conjugate.
A kit for effecting therapy of a tumor in a patient, comprising, in separate containers:
- (A) a first conjugate comprising a targeting moiety, a first member of a binding pair, and a first therapeutic agent, wherein the targeting moiety selectively binds to a marker substance produced by or associated with a tumor;
- (B) optionally, a clearing agent;
- and
- (C) a second conjugate comprising a complementary member of the binding pair and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent.
A method for effecting therapy of a tumor in a patient comprising:
- (A) administering to the patient a first conjugate comprising a targeting moiety, a first member of a binding pair, and a first therapeutic agent, wherein the targeting moiety selectively binds to a marker substance produced by or associated with a tumor, and allowing the first conjugate to localize at the tumor, thereby effecting therapy of the tumor;
- (B) optionally, administering to the patient a clearing agent, and allowing the clearing agent to clear non-localized first conjugate from circulation;
- and
- (C) administering to the patient a second conjugate comprising a complementary member of the binding pair and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent, and allowing the second conjugate to localize at the tumor, thereby effecting therapy of the tumor.
A composition for effecting therapy of a tumor in a patient, comprising:
- (A) a first conjugate comprising a multispecific targeting moiety which binds to at least one epitope on a marker substance produced by or associated with the tumor cells and with at least one epitope of a component of the second conjugate, a first member of a binding pair, and a first therapeutic agent;
- (B) optionally, a clearing agent;
- and
- (C) a second conjugate comprising a complementary member of said binding pair and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent.
Dependencies are inferred from the claim text.